Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (11)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Abi-Nassif, S.
Right arrow Articles by Hallisey, R. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Abi-Nassif, S.
Right arrow Articles by Hallisey, R. K., Jr
(Chest. 2003;124:406-410.)
© 2003 American College of Chest Physicians

Pegylated Interferon and Ribavirin-Induced Interstitial Pneumonitis With ARDS*

Sandra Abi-Nassif, PharmD; Eugene J. Mark, MD; Robert B. Fogel, MD and Robert K. Hallisey, Jr, MS

* From the Department of Pharmacy (Dr. Abi-Nassif and Mr. Hallisey), the Department of Medicine (Dr. Fogel), Division of Pulmonary and Critical Care, and the Department of Pathology (Dr. Mark), Massachusetts General Hospital, Boston, MA.

Correspondence to: Sandra Abi-Nassif, PharmD, Attending Pharmacist, Department of Pharmacy, MGH, Room GRB 005, 55 Fruit St, Boston, MA 02114; e-mail: sabinassif{at}partners.org

A 49-year-old man with cirrhosis due to hepatitis C virus developed interstitial pneumonitis documented by surgical lung biopsy specimen evaluation after two weekly doses of pegylated interferon-{alpha}2b in combination with ribavirin. He developed ARDS and died after 26 days of hospitalization from multisystem organ failure. This case suggests that interstitial pulmonary disease can occur with pegylated interferon-{alpha}2b therapy.

Key Words: ARDS • interferon-{alpha} • interstitial lung disease






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American College of Chest Physicians.